Your Messages Inbox
Your Article Summary
See Latest ArticlesArzoxifene: the evidence for its development in the management of breast cancer
Core Evidence, 08/18/09
Jackson LR et al. – Despite early promise as the "ideal SERM", results from a phase III trial have relegated arzoxifene to research in breast cancer prevention and osteoporosis treatment.
Related Articles
Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers
Journal of Clinical Oncology, 10/29/09
Relevance Score: 74%
Advanced Breast Cancer and Breast Cancer Mortality in Randomized Controlled Trials on Mammography Screening
Journal of Clinical Oncology, 11/09/09
Relevance Score: 72%
Adipocyte fatty acid-binding protein as a novel prognostic factor in obese breast cancer patients
Breast Cancer Research and Treatment, 10/27/09
Relevance Score: 72%
Underweight and breast cancer recurrence and death: A report from the Korean breast cancer society
Journal of Clinical Oncology, 10/08/09
Relevance Score: 72%
Reduced prediagnostic 25-hydroxyvitamin D levels in women with breast cancer: a nested case-control study
Cancer Epidemiology, Biomarkers & Prevention, 10/01/09
Relevance Score: 72%
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Bayer Starts Phase III Trial with Florbetaben
BayNews International, 12/01/09
Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: A randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers
Clinical Therapeutics, 12/01/09
Directly observed antiretroviral therapy: a systematic review and meta-analysis of randomised clinical trials
The Lancet - Early Online Publication, 12/01/09
Article Search
Sponsor